학술논문

Panitumumab plus trifluridine/tipiracil as anti-EGFR rechallenge therapy in patients with refractory RAS wild-type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial
Document Type
Article
Source
In: International Journal of Cancer. (International Journal of Cancer, 15 October 2023, 153(8):1520-1528)
Subject
Language
English
ISSN
10970215
00207136